Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) have been given an average recommendation of “Hold” by the nine brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $5.00.

Separately, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research report on Tuesday, January 16th.

How to Become a New Pot Stock Millionaire

ACRX stock traded up $0.20 during trading on Wednesday, hitting $2.45. 607,998 shares of the stock traded hands, compared to its average volume of 430,128. AcelRx Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $5.75. The company has a market capitalization of $114.52, a price-to-earnings ratio of -2.14 and a beta of 2.41. The company has a debt-to-equity ratio of -0.31, a quick ratio of 4.57 and a current ratio of 4.64.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20). The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $2.90 million. research analysts predict that AcelRx Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

An institutional investor recently raised its position in AcelRx Pharmaceuticals stock. Geller Family Office Services LLC boosted its position in shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) by 175.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 275,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 175,000 shares during the quarter. AcelRx Pharmaceuticals comprises about 0.3% of Geller Family Office Services LLC’s holdings, making the stock its 17th biggest holding. Geller Family Office Services LLC owned 0.55% of AcelRx Pharmaceuticals worth $557,000 at the end of the most recent reporting period. 9.20% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Analysts Set AcelRx Pharmaceuticals (ACRX) Price Target at $5.00” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/04/16/analysts-set-acelrx-pharmaceuticals-acrx-price-target-at-5-00.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.